Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants

Bates, Timothy A.; McBride, Savannah K.; Leier, Hans C.; Guzman, Gaelen; Lyski, Zoe L.; Schoen, Devin; Winders, Bradie; Lee, Joon-Yong; Lee, David Xthona; Messer, William B.; Curlin, Marcel E.; Tafesse, Fikadu G.

doi:10.1126/sciimmunol.abn8014

Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants

Journal Article · Fri Feb 18 00:00:00 EST 2022 · Science Immunology

DOI:https://doi.org/10.1126/sciimmunol.abn8014· OSTI ID:1907939

^[1]; ^[1]; ^[1]; ^[1]; ^[1]; ^[1]; Winders, Bradie ^[1]; ^[2]; ^[1]; ^[1]; ^[1]; ^[1]

Oregon Health and Science University, Portland, OR (United States)
Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)

Current coronavirus disease 2019 (COVID-19) vaccines effectively reduce overall morbidity and mortality and are vitally important to controlling the pandemic. Individuals who previously recovered from COVID-19 have enhanced immune responses after vaccination (hybrid immunity) compared with their naïve-vaccinated peers; however, the effects of post-vaccination breakthrough infections on humoral immune response remain to be determined. Here, we measure neutralizing antibody responses from 104 vaccinated individuals, including those with breakthrough infections, hybrid immunity, and no infection history. We find that human immune sera after breakthrough infection and vaccination after natural infection broadly neutralize SARS-CoV-2 (severe acute respiratory coronavirus 2) variants to a similar degree. Although age negatively correlates with antibody response after vaccination alone, no correlation with age was found in breakthrough or hybrid immune groups. Together, our data suggest that the additional antigen exposure from natural infection substantially boosts the quantity, quality, and breadth of humoral immune response regardless of whether it occurs before or after vaccination.

View Accepted Manuscript (DOE)

Research Organization:: Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)

Sponsoring Organization:: M. J. Murdock Charitable Trust; National Institutes of Health (NIH); OHSU Foundation; USDOE

Grant/Contract Number:: AC05-76RL01830

OSTI ID:: 1907939

Report Number(s):: PNNL-SA-173159

Journal Information:: Science Immunology, Journal Name: Science Immunology Journal Issue: 68 Vol. 7; ISSN 2470-9468

Publisher:: AAASCopyright Statement

Country of Publication:: United States

Language:: English

References (25)

Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples Bates, Timothy A.; Leier, Hans C.; Lyski, Zoe L. JAMA, Vol. 326, Issue 9 https://doi.org/10.1001/jama.2021.11656	journal	September 2021
Association of Age With SARS-CoV-2 Antibody Response Yang, He S.; Costa, Victoria; Racine-Brzostek, Sabrina E. JAMA Network Open, Vol. 4, Issue 3 https://doi.org/10.1001/jamanetworkopen.2021.4302	journal	March 2021
Data, disease and diplomacy: GISAID's innovative contribution to global health: Data, Disease and Diplomacy Elbe, Stefan; Buckland-Merrett, Gemma Global Challenges, Vol. 1, Issue 1 https://doi.org/10.1002/gch2.1018	journal	January 2017
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study Tartof, Sara Y.; Slezak, Jeff M.; Fischer, Heidi The Lancet, Vol. 398, Issue 10309 https://doi.org/10.1016/S0140-6736(21)02183-8	journal	October 2021
An interactive web-based dashboard to track COVID-19 in real time Dong, Ensheng; Du, Hongru; Gardner, Lauren The Lancet Infectious Diseases, Vol. 20, Issue 5 https://doi.org/10.1016/S1473-3099(20)30120-1	journal	May 2020
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity Rydyznski Moderbacher, Carolyn; Ramirez, Sydney I.; Dan, Jennifer M. Cell, Vol. 183, Issue 4 https://doi.org/10.1016/j.cell.2020.09.038	journal	November 2020
COVID-19-neutralizing antibodies predict disease severity and survival Garcia-Beltran, Wilfredo F.; Lam, Evan C.; Astudillo, Michael G. Cell, Vol. 184, Issue 2 https://doi.org/10.1016/j.cell.2020.12.015	journal	January 2021
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner Keeton, Roanne; Richardson, Simone I.; Moyo-Gwete, Thandeka Cell Host & Microbe, Vol. 29, Issue 11 https://doi.org/10.1016/j.chom.2021.10.003	journal	November 2021
Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population Butt, Adeel A.; Yan, Peng; Shaikh, Obaid S. EClinicalMedicine, Vol. 40 https://doi.org/10.1016/j.eclinm.2021.101117	journal	October 2021
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples Ackerman, Margaret E.; Moldt, Brian; Wyatt, Richard T. Journal of Immunological Methods, Vol. 366, Issue 1-2 https://doi.org/10.1016/j.jim.2010.12.016	journal	March 2011
Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum Bates, Timothy A.; Leier, Hans C.; Lyski, Zoe L. Nature Communications, Vol. 12, Issue 1 https://doi.org/10.1038/s41467-021-25479-6	journal	August 2021
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection Wang, Zijun; Muecksch, Frauke; Schaefer-Babajew, Dennis Nature, Vol. 595, Issue 7867 https://doi.org/10.1038/s41586-021-03696-9	journal	June 2021
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses Turner, Jackson S.; O’Halloran, Jane A.; Kalaidina, Elizaveta Nature, Vol. 596, Issue 7870 https://doi.org/10.1038/s41586-021-03738-2	journal	June 2021
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies Chen, Rita E.; Zhang, Xianwen; Case, James Brett Nature Medicine, Vol. 27, Issue 4 https://doi.org/10.1038/s41591-021-01294-w	journal	March 2021
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 Falsey, Ann R.; Frenck, Robert W.; Walsh, Edward E. New England Journal of Medicine, Vol. 385, Issue 17 https://doi.org/10.1056/NEJMc2113468	journal	October 2021
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Polack, Fernando P.; Thomas, Stephen J.; Kitchin, Nicholas New England Journal of Medicine, Vol. 383, Issue 27 https://doi.org/10.1056/NEJMoa2034577	journal	December 2020
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant Lopez Bernal, Jamie; Andrews, Nick; Gower, Charlotte New England Journal of Medicine, Vol. 385, Issue 7 https://doi.org/10.1056/NEJMoa2108891	journal	August 2021
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers Bergwerk, Moriah; Gonen, Tal; Lustig, Yaniv New England Journal of Medicine, Vol. 385, Issue 16 https://doi.org/10.1056/NEJMoa2109072	journal	October 2021
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months Thomas, Stephen J.; Moreira, Edson D.; Kitchin, Nicholas New England Journal of Medicine, Vol. 385, Issue 19 https://doi.org/10.1056/NEJMoa2110345	journal	November 2021
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel Bar-On, Yinon M.; Goldberg, Yair; Mandel, Micha New England Journal of Medicine, Vol. 385, Issue 15 https://doi.org/10.1056/NEJMoa2114255	journal	October 2021
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months Levin, Einav G.; Lustig, Yaniv; Cohen, Carmit New England Journal of Medicine, Vol. 385, Issue 24 https://doi.org/10.1056/NEJMoa2114583	journal	December 2021
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific Memory B Cells From Individuals With Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern Lyski, Zoe L.; Brunton, Amanda E.; Strnad, Matt I. The Journal of Infectious Diseases, Vol. 225, Issue 6 https://doi.org/10.1093/infdis/jiab585	journal	December 2021
Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus Katzelnick, Leah C.; Coello Escoto, Ana; McElvany, Benjamin D. PLOS Neglected Tropical Diseases, Vol. 12, Issue 10 https://doi.org/10.1371/journal.pntd.0006862	journal	October 2018
Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 Cavanaugh, Alyson M.; Spicer, Kevin B.; Thoroughman, Douglas MMWR. Morbidity and Mortality Weekly Report, Vol. 70, Issue 32 https://doi.org/10.15585/mmwr.mm7032e1	journal	August 2021
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021 Nanduri, Srinivas; Pilishvili, Tamara; Derado, Gordana MMWR. Morbidity and Mortality Weekly Report, Vol. 70, Issue 34 https://doi.org/10.15585/mmwr.mm7034e3	journal	August 2021

Cited By (1)

Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone da Silva, Eveline Santos; Kohnen, Michel; Gilson, Georges International Journal of Molecular Sciences, Vol. 23, Issue 14 https://doi.org/10.3390/ijms23147675	journal	July 2022

Similar Records

Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination

Journal Article · Tue May 17 20:00:00 EDT 2022 · Nature (London) · OSTI ID:2470778

Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost

Journal Article · Sun Mar 05 19:00:00 EST 2023 · iScience · OSTI ID:1961384

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Journal Article · Mon Aug 09 20:00:00 EDT 2021 · Science · OSTI ID:2471339

Related Subjects

60 APPLIED LIFE SCIENCES

Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants

Citation Formats

References (25)

Cited By (1)

Similar Records

Related Subjects